IE901736L - Polypeptide-antibody conjugate for inhibiting cell adhesion - Google Patents

Polypeptide-antibody conjugate for inhibiting cell adhesion

Info

Publication number
IE901736L
IE901736L IE901736A IE173690A IE901736L IE 901736 L IE901736 L IE 901736L IE 901736 A IE901736 A IE 901736A IE 173690 A IE173690 A IE 173690A IE 901736 L IE901736 L IE 901736L
Authority
IE
Ireland
Prior art keywords
polypeptide
cell adhesion
antibody conjugate
inhibiting cell
disclosed
Prior art date
Application number
IE901736A
Original Assignee
Fuller H B Licensing Financ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuller H B Licensing Financ filed Critical Fuller H B Licensing Financ
Publication of IE901736L publication Critical patent/IE901736L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A polypeptide-antibody conjugate is disclosed that contains an integrin-binding polypeptide operatively attached to an antibody molecule that immunoreacts with adhesitory cell surface antigens. Therapeutic compositions and methods using those compositions are also disclosed whereby the polypeptide-antibody conjugate can be used to inhibit cell adhesion and cell adhesion-dependent processes such as tumor growth and platelet aggregation. [WO9014103A1]
IE901736A 1989-05-17 1990-05-14 Polypeptide-antibody conjugate for inhibiting cell adhesion IE901736L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36261789A 1989-05-17 1989-05-17

Publications (1)

Publication Number Publication Date
IE901736L true IE901736L (en) 1990-11-17

Family

ID=23426812

Family Applications (1)

Application Number Title Priority Date Filing Date
IE901736A IE901736L (en) 1989-05-17 1990-05-14 Polypeptide-antibody conjugate for inhibiting cell adhesion

Country Status (6)

Country Link
AU (1) AU5815990A (en)
CA (1) CA2016962A1 (en)
GR (1) GR900100372A (en)
IE (1) IE901736L (en)
PT (1) PT94067A (en)
WO (1) WO1990014103A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
JP3283041B2 (en) * 1990-07-13 2002-05-20 学校法人藤田学園 Artificial antibody
CA2109332A1 (en) * 1991-05-03 1992-11-04 Elaine Tuomanen Antibody recognizing endothelial cell ligand for leukocyte cr3
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE216402T1 (en) * 1997-11-07 2002-05-15 Conjuchem Inc OPIOID CONJUGATES WITH ENDOGENE CARRIER PROTEINS
JP2003509468A (en) * 1999-09-23 2003-03-11 ザ・スクリプス・リサーチ・インステイチユート Methods and compositions for inhibiting adhesion formation
DK1272507T3 (en) 2000-04-12 2005-10-03 Amersham Health As Integrin-binding peptide derivatives
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
EP2347771A1 (en) 2001-07-10 2011-07-27 Ge Healthcare As Peptide-based compounds for targeted imaging
JP2012513589A (en) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド Application of 99mTc-peptide compounds as bone marrow imaging agents
WO2011112549A2 (en) * 2010-03-10 2011-09-15 Emory University Temperature sensitive conjugate compositions, and uses related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins

Also Published As

Publication number Publication date
WO1990014103A1 (en) 1990-11-29
CA2016962A1 (en) 1990-11-17
GR900100372A (en) 1991-10-10
AU5815990A (en) 1990-12-18
PT94067A (en) 1991-02-08

Similar Documents

Publication Publication Date Title
IE901736L (en) Polypeptide-antibody conjugate for inhibiting cell adhesion
USD292563S (en) Flower pot cover
CA2102301A1 (en) Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
CA2017025A1 (en) Tumor necrosis factor binding protein ii, its purification and antibodies thereto
AU549204B2 (en) Intravenously injectable immune serum globulin
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
USD279651S (en) Combined container and closure
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AU591774B2 (en) Lysine salt of the gadolinium-dota complex and its applications to diagnosis
AU2460988A (en) Simultaneous immunoassay for the determination of antigens and antibodies
AU519091B2 (en) Protein concentrate containing immunological factors of lactic origin
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
AU3533689A (en) Tight binding of proteins to surfaces
CA956279A (en) Valve pour la distribution d'un ou de plusieurs fluides pressurises
EP0212807A3 (en) Coloured compound containing a cationic group and a reactive group
AU567747B2 (en) Early detection of mammalian pregnancy
IE832452L (en) Lymphocyte growth factor
AU550364B2 (en) Immunogen of lidocaine-protein conjugate and antibodies derived therefrom
IL82930A (en) Antibodies for the detection of mammalian carcinomas and their preparation
USD284318S (en) Wig anchor
GR860229B (en) Monoclonal antibody against a ras oncogene p21 relatied dodecapeptide
AU7912887A (en) Monoclonal antibodies to fibrin
AU6663990A (en) Chimeric mouse-human antibodies with specificity to hiv antigens
USD284935S (en) Planting pot clamp for suspended supports
AU2684388A (en) Peptides acting to influence the mammalian pituitary